Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.

Duffaud, Florence; Schiffler, Camille; Chabaud, Sylvie; Blay, Jean-Yves

Duffaud, Florence; Schiffler, Camille; Chabaud, Sylvie; Blay, Jean-Yves.

Afiliação

Duffaud F; Aix Marseille University, APHM Hopital La Timone, Medical Oncology Unit, Marseille, France. Electronic address: Florence.DUFFAUD@ap-hm.fr.
Schiffler C; Department of Statistics, Centre Léon Bérard, Lyon, France.
Chabaud S; Department of Statistics, Centre Léon Bérard, Lyon, France.
Blay JY; Medical Oncology Department, Centre Léon Bérard, Lyon, France.

Eur J Cancer ; 157: 527-528, 2021 11.

Article em En | MEDLINE | ID: mdl-34509346

Assuntos

Condrossarcoma; Compostos de Fenilureia; Método Duplo-Cego; Humanos; Compostos de Fenilureia/efeitos adversos; Piridinas/efeitos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Condrossarcoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google